Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma

Hepatobiliary and Pancreatic Diseases International

Volumn 8, Issue 3, 2009, Pages 282-287

  Mao, Chen Yu ^a,b   Hua, Han Ju ^a   Chen, Ping ^b   Yu, De Chao ^a   Cao, Jiang ^b   Teng, Li Song ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Chemotherapy; Drug resistance; Hepatocellular carcinoma; Oncolytic adenovirus

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN; FLUOROURACIL; ONCOLYTIC ADENOVIRUS; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SPECIFICITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; TUMOR VOLUME;

ADENOVIRIDAE; ALPHA-FETOPROTEINS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; ONCOLYTIC VIROTHERAPY; PACLITAXEL; TREATMENT OUTCOME;

EID: 67549137560     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, et al. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 2005;25:367-379. (Pubitemid 40500573)
3. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998;17:3247-3259. (Pubitemid 29043977)
4. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-376. (Pubitemid 26353341)
5. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic antitumoral efficacy. Nat Med 2000;6:1134-1139. (Pubitemid 30792193)
6. Steinwaerder DS, Carlson CA, Otto DL, Li ZY, Ni S, Lieber A. Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector. Nat Med 2001;7:240-243. (Pubitemid 32148493)
7. Ramachandra M, Rahman A, Zou A, Vaillancourt M, Howe JA, Antelman D, et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 2001;19:1035-1041. (Pubitemid 33041887)
8. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000;106:763-771. (Pubitemid 30727594)
9. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006;14:107-117. (Pubitemid 43899483)
10. Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001;61:6012-6019. (Pubitemid 32762530)
11. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007;7:141-148. (Pubitemid 46348628)
12. Li JL, Liu HL, Zhang XR, Xu JP, Hu WK, Liang M, et al. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther 2009;16:376-382.
13. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001;61:6428-6436. (Pubitemid 32783248)
14. Jounaidi Y, Doloff JC, Waxman DJ. Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets 2007;7:285-301. (Pubitemid 46699079)
15. Kubicka S, Rudolph KL, Hanke M, Tietze MK, Tillmann HL, Trautwein C, et al. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver 2000;20:312-318. (Pubitemid 30488002)
16. Park YM, Choi JY, Byun BH, Cho CH, Kim HS, Kim BS. Telomerase is strongly activated in hepatocellular carcinoma but not in chronic hepatitis and cirrhosis. Exp Mol Med 1998;30:35-40. (Pubitemid 28181770)
17. Kawakami Y, Kitamoto M, Nakanishi T, Yasui W, Tahara E, Nakayama J, et al. Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues. Oncogene 2000;19:3888-3893. (Pubitemid 30658979)
18. Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 2006;32:28-44. (Pubitemid 43159775)
19. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-234. (Pubitemid 43336035)
20. D'Alessandro N, Poma P, Montalto G. Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful? World J Gastroenterol 2007;13:2037-2043.
21. Montero J, Morales A, Llacuna L, Lluis JM, Terrones O, Basanez G, et al. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res 2008;68:5246-5256.
22. Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 2001;94:492-499.
23. Alisi A, Balsano C. Enhancing the efficacy of hepatocellular carcinoma chemotherapeutics with natural anticancer agents. Nutr Rev 2007;65:550-553. (Pubitemid 351804337)
24. Lau CK, Yang ZF, Lam SP, Lam CT, Ngai P, Tam KH, et al. Inhibition of Stat3 activity by YC-1 enhances chemosensitivity in hepatocellular carcinoma. Cancer Biol Ther 2007;6:1900-1907.
25. Barraud L, Merle P, Soma E, Lefrancois L, Guerret S, Chevallier M, et al. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol 2005;42:736-743. (Pubitemid 40501691)
26. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004;10:5299-5312. (Pubitemid 39100464)
27. Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008;10:371-379.
28. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001;61:517-525. (Pubitemid 32128610)
29. Jounaidi Y. Cytochrome P450-based gene therapy for cancer treatment: from concept to the clinic. Curr Drug Metab 2002;3:609-622. (Pubitemid 35331662)